CBD and THC have the same formula: C21H30O2

CBD and THC have the same molecular formula. Not similar — the same: C₂₁H₃₀O₂. Twenty-one carbon atoms, thirty hydrogens, two oxygens, in both.

They are structural isomers. Same ingredients, different assembly. The entire difference between a compound sold in supermarkets and a compound that is controlled almost everywhere comes down to whether one ring in the structure is closed or left open.

Everything else on this page follows from that single fact — including the part almost nobody writes down: because the two are that close, the industry converts one into the other, and that is why regulators write laws about a threshold rather than about a plant.

The same atoms, arranged differently

What “structural isomer” means here

Two molecules can share a formula and behave nothing alike, because chemistry is about arrangement as much as composition. Graphite and diamond are both carbon, and nobody would call them similar materials. CBD and THC are both C₂₁H₃₀O₂, and the same caution applies.

The one difference

In THC, part of the structure has cyclised — a ring has closed. In CBD, that same portion remains open, leaving a free hydroxyl group where THC has a ring.

That is it. That is the whole structural story, and it is the reason the two behave so differently at one specific place in the body.

Why the shape decides the behaviour

Receptors work by fit. The CB1 receptor, concentrated in the brain, accommodates the closed-ring shape of THC and binds it. CBD’s open-ring shape does not fit the same way, and CBD binds CB1 only weakly.

That is the mechanism behind the single most repeated sentence about these compounds — THC is intoxicating and CBD is not. It is not a difference of strength or dose. It is a difference of shape.

What each one does at the receptor

THC is a partial agonist at CB1

It binds and activates, though not maximally. That “partial” matters more than it sounds: it means there is a ceiling to the effect built into the pharmacology. Fully synthetic cannabinoids designed in laboratories are often full agonists, which is precisely why they are far more dangerous than THC despite acting on the same receptor.

CBD is not doing the same job

CBD’s activity is not well described as CB1 activation. The review literature describes a much broader and less tidy pharmacology, including interactions with non-cannabinoid targets, and this is one reason its effects are harder to characterise than THC’s.

The honest summary: the mechanism by which THC intoxicates is well understood; what CBD does is still being mapped.

Why the law measures THC and never CBD

This is where the chemistry turns into paperwork, and where most explanations stop too early.

Thresholds, not bans

Almost no jurisdiction regulates CBD by quantity. What they regulate is the THC content of the plant or product, expressed as a percentage of dry weight:

The United Kingdom does it differently

The UK is the outlier worth knowing about, because it does not primarily use a percentage. It works from a per-container limit on controlled cannabinoids — a maximum quantity in the finished product rather than a proportion of it.

That distinction matters more than it looks. A percentage of weight scales with the size of the product; a fixed quantity does not. It is the reason a product legal on one side of the Channel can fail on the other while containing exactly the same concentration.

Why a percentage of weight is a strange unit

Because it scales with the carrier. Zero point three percent of a gram of flower is 3 mg. Zero point three percent of a five-gram gummy is 15 mg — of the same compound, under the same rule.

The threshold was written to classify a plant. Applied to manufactured food, it permits an absolute quantity the rule was never designed to allow — and the heavier the product, the wider that gap becomes.

Drug tests: the asymmetry that catches people out

Tests look for THC

Standard workplace and roadside screening targets THC and its metabolites. CBD is not what is being looked for. A pure CBD isolate does not produce a positive result for THC, because there is no THC in it.

Why people still fail

Because most CBD products are not isolates. A full-spectrum extract legally contains THC below the threshold — and a screening test does not ask where the THC came from or whether the product was lawful.

That is the asymmetry: the law permits a small amount, and the test does not care that it was permitted.

What to do about it

If a test matters to you, the format is the decision, not the brand. An isolate excludes THC by construction. A broad-spectrum product is suitable only if the batch certificate shows a figure or the notation < LOQ on the THC line — the words “THC free” on the box are not the same claim.

Because they are that close, one becomes the other

This is the section that separates a chemistry explainer from a useful page, and it is the consequence almost nobody spells out.

CBD can be converted into THC

The structural gap is one ring closure, and ring closures are ordinary chemistry. Under acidic conditions, CBD cyclises. The conversion is well documented and it is not difficult.

This is where the novel cannabinoids came from

Hemp-derived CBD became abundant and cheap. A cheap starting material one reaction away from controlled compounds is an obvious commercial temptation, and the market took it: HHC, THC-O and the rest of the semi-synthetic wave were manufactured from hemp CBD, not extracted from cannabis.

France banned HHC in 2023. Czech authorities placed it among prohibited substances. The pattern was the same everywhere: a compound appears, is sold as legal because no statute names it, and is named within a year or two.

Why this reframes the whole question

If you only know that “CBD is legal and THC is not”, the existence of these compounds looks like a loophole. Once you know the two are isomers, it looks like what it is — an inevitability of the chemistry, which is exactly why regulators moved from naming molecules to setting thresholds.

What the research separates, and what it does not

THC has a clear pharmacological story

Intoxication, receptor binding, dose relationship: the mechanism is established, and so are the risks associated with it.

CBD has one approved medicine and a lot of open questions

There is exactly one cannabidiol medicine authorised in Europe, assessed by the European Medicines Agency, prescribed for defined indications. Its assessment report is the most rigorous data we have on cannabidiol in humans — and the amounts used in it are orders of magnitude above what a supplement contains.

No authorised health claim

In the European Union there is no authorised health claim for CBD. That is not a paperwork detail. It means the dossiers submitted were not judged sufficient.

The World Health Organization’s expert committee concluded in its critical review that pure cannabidiol is generally well tolerated and does not exhibit abuse potential in the sense of the relevant criteria. Both statements are true at once, and holding them together is the honest position: well tolerated is not the same as demonstrated to do something.

The other cannabinoids, placed on the same map

Once you know CBD and THC are isomers, the rest of the alphabet stops looking like a random list.

CBDA and THCA — the acid forms

What the living plant actually produces. Both carry an extra carboxyl group, and heat removes it — decarboxylation. Raw plant material is largely acid forms; a finished extract is largely the neutral ones.

This is why a tea brewed from raw flower delivers mostly CBDA rather than CBD, and why the conversion factor 0.877 exists at all.

CBN — what THC becomes when it ages

Cannabinol is not manufactured by the plant in quantity. It appears through the degradation of THC under time, light and oxygen. An extract rich in CBN is, by construction, one that has aged or been deliberately oxidised.

It is sold as the “sleep cannabinoid”, a claim that traces back to old work in which CBN was given together with THC — attributing the observation to CBN alone is a shortcut the more recent literature does not support.

CBG — the one they all come from

Often called the precursor, because CBGA is the acid the plant converts into the other acids. It is the branch point rather than a variant.

Why the naming looks confusing and is not

Three letters, a suffix, and one of four states: acid or neutral, natural or degraded. Once the map is that simple, a shop selling a “new cannabinoid” is easy to place — and the semi-synthetics from the previous section are the ones that fit nowhere on it, because the plant does not make them.

What the difference means at the shelf

The label word that matters is “spectrum”

Not the percentage, not the brand, not the word premium. Three options, one consequence:

• Full spectrum — all plant compounds, THC included below the threshold.
• Broad spectrum — the same minus THC, removed after extraction.
• Isolate — cannabidiol only.

The certificate is where the difference becomes a number

A batch certificate lists both compounds separately, with figures. Everything on this page turns into a practical decision at that one line — and a product whose certificate is not available without creating an account has not answered the question.

Why “hemp-derived” is not the reassurance it sounds like

The phrase describes where a compound came from, not what it is. Hemp-derived CBD is CBD; so is CBD from any other cultivar, because a molecule has no memory of its origin.

More importantly, hemp-derived is exactly what the semi-synthetics of the previous section were: made from hemp CBD, marketed on that provenance, and controlled within two years in most of Europe. Origin is a supply-chain fact. What is in the bottle is a certificate fact.

The arithmetic trap that applies to both

Certificates often report CBDA alongside CBD, because the living plant makes the acid form. Heat converts it, losing a CO₂ molecule in the process, so the conversion factor is 0.877:

Total CBD = CBD + (CBDA × 0.877)

A seller who adds CBDA without applying the factor reports roughly 14 % more than is present. The same acid-form logic applies to THC and THCA, which is why some certificates show both.

The questions Google shows for this search

“Do you feel a buzz from CBD?”

No — and the reason is structural, not a matter of quantity. CBD does not meaningfully activate CB1. If a product produces intoxication, the explanation is what else is in it.

“Will CBD fail a drug test?”

CBD itself is not screened for. THC is, and full-spectrum products lawfully contain it. Covered in full above.

“Who should avoid taking CBD?”

The most substantial answer concerns interactions rather than side effects. Cannabidiol is metabolised by liver enzymes of the CYP family — notably CYP3A4 and CYP2C19 — and can affect how quickly the body processes other substances using the same pathway. It is the same mechanism behind grapefruit warnings on many medicine leaflets.

Anyone on regular medication should raise it with a doctor or pharmacist before starting. The same applies during pregnancy and breastfeeding, where the guidance from European authorities is unambiguous because the safety data are insufficient.

“Why don’t doctors recommend CBD?”

Because caution matches the state of the evidence. There is one approved medicine and a large volume of consumer products sold at amounts nobody has studied properly. A clinician declining to endorse the second is not dismissing the first, and the distinction is worth keeping in mind before reading reluctance as prejudice.

Where the two are legally separated, and where they are not

A closing distinction that decides more purchases than the pharmacology does.

The plant is one thing, the product is another

No jurisdiction on our list bans cannabidiol. What they regulate is a plant by its THC content and then, separately, the category a finished product falls into. Those are two different gates, and a product can pass the first and fail the second.

An oil below the threshold is lawful as plant material and still unauthorised as food, because cannabinoid extracts for ingestion sit under the European novel food regulation and no CBD extract has been authorised.

Which is why the same extract wears different clothes

In Spain it is labelled for external use. In Germany it is an aroma product. In Denmark an oral CBD product is classed as a medicine by function, so the only lawful ones are prescription-only. In the Czech Republic it sits on a pharmacy shelf as a food supplement.

Same molecule, same threshold, four different shelves. The variation is not about THC at all — it is about which regulatory category each country decided the finished product belongs to, and that decision was made separately in each capital.

What that means when you buy across a border

The product is judged by the rules of the country it ends up in, not the one it shipped from. A Czech product at 0.8 % THC is entirely lawful at home and above the limit almost everywhere else. The figure on the certificate is the one to compare against your own threshold — and it is rarely in the product description.

The reference figure worth knowing

The European Food Safety Authority published an updated assessment on 9 February 2026 with a reference value of 0.0275 mg per kilogram of body weight per day — roughly 2 mg daily for a 70 kg adult.

That is far below what most labels suggest, and it is explicitly a safety assessment rather than a serving recommendation. We report it because it belongs to the subject, and we draw no recommendation from it: the assessment is expressly not closed.

What we check, and what we do not

We check what can be verified from documents: molecular facts, regulatory texts, assessment reports, arithmetic. We do not test products, and we publish no rankings.

On this particular question the limit costs us nothing, because the answer is not a matter of opinion. Two molecules either share a formula or they do not. One ring is either closed or open. And a certificate either lists a figure on the THC line or it does not.

That is the useful thing about starting from chemistry: it is the one part of this subject where nobody gets to have a view.

Everything downstream of it is where the disagreement lives — what CBD does, whether it is worth buying, which brand to trust. We take positions on none of those, and the reason is consistent: we have not tested any product, and a ranking would imply otherwise.

What we can hand you instead is the shape of the question. Same formula, one ring, one threshold, one line on a certificate. If you remember only that the difference between these two compounds is structural rather than a matter of degree, most of the confusing claims in this market sort themselves out on their own.